Ipsen Seeks Success Outside Big Pharma's Hunting Grounds

Keen On Drugs With Peak Sales Of $300m-800m

David Loew has assembled a strong business development team which secured seven licensing pacts in 2021 and the Ipsen CEO tells Scrip that this year should see more of the same.

David Loew
David Loew • Source: Ipsen

The perception of Ipsen SA as a conservative business has been turned on its head since David Loew took over as CEO in July 2020, with the French company becoming a flagbearer for mid-sized pharma business development, having signed off seven external pacts last year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business